Discovery of novel oridonin sulfamide derivatives as potent NLRP3 inhibitors by a visible-light photocatalysis-enabled peripheral editing

The progress of organic synthetic method can promote late -stage lead compound modification and novel active compound discovery. Molecular editing technology in the field of organic synthesis, including peripheral and skeletal editing, facilitates rapid access to molecular diversity of a lead compound. Peripheral editing of C-H bond activation is gradually used in lead optimization to afford novel active scaffolds and chemical space exploitation. To develop oridonin derivatives with high anti-inflammatory potency, novel oridonin sulfamides had been designed and synthesized by a scaffold hopping strategy based on a visible -light photocatalysis peripheral editing. All novel compounds revealed measurable inhibition of IL-1 beta and low cytotoxicity in THP-1 cells. The docking study indicated that the best active compound ZM640 was accommodated in the binding site of NLRP3 with two hydrogen bond interaction. These preliminary results confirm that alpha, beta-unsaturated carbonyl of oridonin is not essential for NLRP3 inhibitory effect. This new oridonin scaffold has its potential to be further developed as a promising class of NLRP3 inhibitors.